Aura Biosciences Q3 net loss $26.1M; Phase 3 CoMpass data expected Q4 2027

Aura Biosciences, Inc.

2025-Q3 EPS reported -$1.39 vs consensus -$0.48 ▼ miss (-192.1%)

Net loss of $26.1M in Q3 2025 vs $21.0M in Q3 2024; R&D expenses rose to $22.2M from $17.0M.
Cash and marketable securities $161.9M; cash runway into first half 2027.
Phase 3 CoMpass trial in early choroidal melanoma: enrollment completion expected 2026, topline data Q4 2027.
Phase 1b/2 NMIBC trial on track for initial data mid-2026; immune profiling shows cold-to-hot tumor conversion.
First patient dosed in Phase 2 choroidal metastases trial; entry criteria expanded to include all solid tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.